Chargement en cours...
Designing CAR T cells for glioblastoma
Chimeric antigen receptor (CAR)-modified T cells directed against CD19 can mediate long-term durable remissions in B cell malignancies, but bringing a new target antigen to the clinic requires extensive modeling to avoid on-target and off-target toxicity. We recently described a systematic approach...
Enregistré dans:
| Publié dans: | Oncoimmunology |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4635938/ https://ncbi.nlm.nih.gov/pubmed/26587317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1048956 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|